胸腺五肽对肿瘤病儿化疗停药后免疫功能影响

THE EFFECT OF THYMOPENTIN ON IMMUNE FUNCTION IN CHILDREN AFTER CHEMOTHERAPY FOR MALIGNANT TUMOR

目的探讨胸腺五肽(TP-5)对肿瘤病儿化疗停药后免疫功能、感染和用药安全性的影响。方法随机选取20例肿瘤化疗停药病儿为治疗组,给予TP-5肌肉注射(<30kg病儿每次10mg,每周1次;≥30kg病儿每次10mg,每周2次);另随机选取20例肿瘤化疗停药病儿作为对照组,不做任何免疫调节治疗。于停药后3个月检查CD3、CD4+、CD8+、CD4+/CD8+、CD56及IgG、IgM、IgA的水平。定期检测肝肾功能、心电图、血常规。结果治疗组治疗前与对照组细胞免疫水平、NK细胞及体液免疫水平比较差异无显著性(P>0.05);治疗组治疗3个月与同期对照组比较,细胞免疫水平无明显差异(P>0.05),而NK细胞及体液免疫水平较对照组明显提高(t=7.34～9.86,P<0.01)。治疗组治疗3个月间病儿感染发生率和感染控制时间明显小于对照组(χ2=9.23,P<0.01;t=5.40,P<0.01)。治疗组治疗3个月间仅1例出现注射局部疼痛,两组均未出现肝肾功能及心电图的改变。结论TP-5具有改善肿瘤化疗停药后病儿免疫功能的作用,可降低感染发生率,且临床应用安全。

Objective To evaluate the influence of thymopentin （TP-5） on immune function, infection, and safe medieation after chemotherapy in children with malignancy. Methods Forty children with malignancy were equally randomized to two groups： treatment group and control group. TP-5 was administered to the treatment group （for those 〈30 kg of body weight, 10 mg i.m. once a week; for those ≥30 kg, 10 mg, i.m. twice a week）. No immunoregulation therapy was given to the control group. Three months after discontinuation, cell immunity （CD3, CD4^＋ , CD8^＋ , CD4^＋/CD8^＋ ）, natural killer cell function （CD56）, humoral immunity （IgG, IgM and IgA） were measured. Liver and renal functions, ECG and blood routine were tested regularly. Results Before treatment., the differences between the treatment group and control group were not significant in terms of cell immunity, NK cell and humoral immunity （P〉0.05）; after therapy, no significant difference was noted in terms of cell immunity （P〉0. 05）, between the two groups, but NK cell and humoral immunity in treatment group were significantly rose （t=7.34- 9.86, P〈0.01）, and the infection rate was lower and infection-control time shorter （χ^2= 9.23, P〈0.01;t= 5.40, P〈0.01）, only one case had pain in injection part. No liver or renal function or ECG changes were recorded in both groups. Conclusion TP-5 can improve the immune function and decrease infection rate in children with malignant tumor after chemotherapy. It is safe to be used clinically.